Jake Lichterman, D.O. Instructor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Jake Lichterman, D.O., is an Instructor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. Originally from Los Angeles, Dr. Lichterman holds a bachelor's degree in history from the University of California Los Angeles. He earned his medical degree from Touro College of Osteopathic Medicine in New York. He completed internal medicine residency training and fellowship training in hematology and oncology at UT Southwestern as part of the Physician Scientist Training Program. He currently serves as a Postdoctoral Fellow in the Koh Lab. Dr. Lichterman's research focuses on understanding the role of the circadian clock and the gut microbiota in modulating response to immune checkpoint inhibitor therapy. Outside of medicine, he enjoys exploring new cultures through travel and food, supporting his favorite basketball team, the Los Angeles Lakers, and spending time with his family. Education Medical School Touro College of Osteopathic Medicine (2018) Residency UT Southwestern Medical Center (2020), Internal Medicine Fellowship UT Southwestern Medical Center (2024), Hematology Oncology Research Interest Cancer Immunotherapy Circadian rhythms Genitourinary malignancies Gut microbiota Publications Featured Publications Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma. Jang A, Lichterman JN, Zhong JY, Shoag JE, Garcia JA, Zhang T, Barata PC, Hum Vaccin Immunother 2023 Dec 19 3 2276629 Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Choi Y, Lichterman JN, Coughlin LA, Poulides N, Li W, Del Valle P, Palmer SN, Gan S, Kim J, Zhan X, Gao Y, Evers BM, Hooper LV, Pasare C, Koh AY, Sci Immunol 2023 Mar 8 81 eabo2003 Mast Cells: A New Frontier for Cancer Immunotherapy. Lichterman JN, Reddy SM, Cells 2021 May 10 6 A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM Oncotarget 2015 Nov Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hou S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LW, Ke Z, Tseng HR, Posadas EM Cancer 2015 May miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW, Clin Cancer Res 2014 Dec 20 24 6559-69 miR-409-3p/-5p promotes tumorigenesis, epithelial to mesenchymal transition and bone metastasis of human prostate cancer. Josson S, Gururajan M, Hu P, Shao C, Chu CY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW Clin. Cancer Res. 2014 Jun NanoVelcro Chip for CTC enumeration in prostate cancer patients. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM, Methods 2013 Dec 64 2 144-52 Results 1-8 of 8 1 Honors & Awards Research HonorsTouro College of Osteopathic Medicine (2018) Professional Associations/Affiliations American Association for Cancer Research Society for Immunotherapy of Cancer
